Journal: Journal of the National Cancer Institute

Article Title: Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.

doi: 10.1093/jnci/djj003

Figure Lengend Snippet: Fig. 4. Effect of temozolomide on growth arrest DNA damage 34 (GADD34) and ribonucleotide reductase (RR) mRNA and protein; contribution of GADD34 and RR to DNA repair. A ) Results of real-time reverse transcription – polymerase chain reaction analysis of levels of the mRNAs encoding GADD34 and the M2 subunit of RR in drug-treated human astrocytes (HA), U87, T98, U87/MGMT, and U87/mp53 cells. Cells were treated for 48 hours with various concentrations of temozolomide (Tem), cisplatin, or O 6 -benzylguanine (BG). Values shown are relative amounts of mRNA for GADD34 ( solid bars ) and the M2 subunit of RR ( open bars ) compared with untreated cells. Three replicates were performed. Error bars indicate upper 95% confi dence intervals. B ) Western blot analysis of GADD34 expression in U87 cells that were untreated, treated with GADD34 small interfering (si) RNA, treated with 1 mM temozolomide, or treated with temozolomide plus GADD34 siRNA; and RR M2 subunit expression in T98 cells that were treated with 100 μ M O 6 -benzylguanine, O 6 - benzylguanine plus RR small interfering (si)RNA, O 6 -benzylguanine plus 1 mM temozolomide, or O 6 -benzylguanine plus 1 mM temozolomide plus RR siRNA. Blots were probed for actin as a loading control. C ) Results of alkaline comet assay presented as mean tail moment (in arbitrary units; tail moment = % DNA in the tail multiplied by tail distance) as a function of temozolomide concentration for U87 cells treated with RR or GADD34 siRNA and U87/ MGMT cells treated with O 6 -benzylguanine (BG) plus RR or GADD34 siRNA. Experiment was performed three times, each in triplicate. Means of one representative experiment are shown. Error bars indicate 95% confi dence intervals.

Article Snippet: Total protein from cultured cells was extracted in radioimmunoprecipitation assay buffer (150 mM NaCl, 1.0% IGEPAL CA-630; IPEGAL CA-630 = 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, 50 mM Tris, pH 8.0), and 30 μ g of protein was separated by sodium dodecyl sulfate – 8% polyacrylamide gel electrophoresis, transferred to polyvinylidene difl uoride membranes by electroblotting, and incubated with antibodies to GADD34 (goat polyclonal, 1 : 100; Imgenex Corp., San Diego, CA) or RR M2 subunit (chicken polyclonal, 1 : 200; GenWay Biotech, San Diego, CA) at 4 °C overnight.

Techniques: Reverse Transcription, Polymerase Chain Reaction, Western Blot, Expressing, Control, Alkaline Single Cell Gel Electrophoresis, Concentration Assay

Journal: bioRxiv

Article Title: Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

doi: 10.1101/2021.03.04.433896

Figure Lengend Snippet: a) Schematic description of the filtering process for identification of therapeutically relevant target candidates. b) Analysis of RRM2 mRNA expression levels in 50 EwS primary tumors compared to 929 normal tissues samples from 71 tissue types. Data are shown as log2 fold increase normalized to expression values of normal tissues. The dotted line indicates the cut-off value of 2 for candidate selection. c) Analysis of overall survival time of 166 EwS patients stratified for candidate gene expression. P -values (–log10) were determined in Kaplan-Meier analyses using a Mantel-Haenszel test (Bonferroni-adjusted for multiple testing). The dotted line indicates a significance value of 1.3. d) Kaplan-Meier survival analysis of 166 EwS patients stratified by the 78th percentile RRM2 expression. P -value determined by log-rank test.

Article Snippet: Slides were incubated with a polyclonal anti-RRM2 primary antibody (rabbit, 1:500, atlas antibodies, HPA056994) for 60 min at room temperature followed by incubation with a monoclonal secondary horseradish peroxidase (HRP)-coupled horse-anti-rabbit antibody with AEC+ as chromogen, counterstained by hematoxylin Gill’s formula (H-3401, Vector Laboratories, Germany).

Techniques: Expressing, Selection, Gene Expression

Journal: bioRxiv

Article Title: Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

doi: 10.1101/2021.03.04.433896

Figure Lengend Snippet: a) Left: Heat map for gene expression which is positively or negatively correlated with RRM2 expression in 166 EwS. Right: Gene ontology (GO) enrichment analysis of RRM2 and its co-expressed genes derived from gene expression data sets of 166 EwS tumors. Pearson correlation coefficients between RRM2 and other genes were determined, of which those with |r Pearson | > 0.5 were further analyzed by GO enrichment analysis. b) Representative images of immunohistochemical RRM2 staining. Scale bar = 50 µm. c) Kaplan-Meier survival analysis of 122 EwS patients stratified by RRM2 protein expression (low IRS≤2, high IRS >2). P -values were determined by log-rank test. d) WGCNA of downregulated genes upon RRM2 silencing in A-673 and ES-7 cells harboring Dox-inducible shRRM2 constructs. NES, normalized enrichment score. e) Analysis of tumor growth of EwS cell lines A-673 and TC-71 harboring Dox-inducible shRRM2 constructs or non-targeting shRNA (shControl) xenografted in NSG mice. Once tumors were palpable, animals were randomized in Dox (+) or Dox (–) group. Tumor growth on time course and f) Tumor weight at the experimental endpoint. Arrows indicate treatment start. Values are normalized to shControl. Horizontal bars represent means and whiskers SEM. FC, fold change. P -values were calculated at the experimental endpoint with two-sided (tumor growth) or one-sided (tumor weight) Mann-Whitney test. g) Representative micrographs of xenografts immunohistochemically stained for RRM2, cleaved caspase-3 (CC3) or γH2A.X (scale bar=250 µm, 50 µm, 250 µm, respectively). h) quantification of positive cells for cleaved caspase-3 (CC3) (left) and γH2A.X (right). Values were normalized to shControl. Horizontal bars represent means and whiskers SEM. FC, fold change. P -values were calculated at the experimental endpoint using a two-sided Mann-Whitney test.

Article Snippet: Slides were incubated with a polyclonal anti-RRM2 primary antibody (rabbit, 1:500, atlas antibodies, HPA056994) for 60 min at room temperature followed by incubation with a monoclonal secondary horseradish peroxidase (HRP)-coupled horse-anti-rabbit antibody with AEC+ as chromogen, counterstained by hematoxylin Gill’s formula (H-3401, Vector Laboratories, Germany).

Techniques: Gene Expression, Expressing, Derivative Assay, Immunohistochemical staining, Staining, Construct, shRNA, MANN-WHITNEY

Journal: bioRxiv

Article Title: Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

doi: 10.1101/2021.03.04.433896

Figure Lengend Snippet: a) Analysis of proliferation assays upon shRNA-mediated RRM2 silencing in EwS cell lines. Upper: Cell proliferation over 120h upon RRM2 silencing in A-673. Viable cells upon RRM2 silencing (middle) and dead cells (lower) in EwS cell lines (A-673, ES7, TC-71) harboring Dox-inducible shRRM2 constructs or non-targeting shRNA (shControl). Values are normalized to shControl. Horizontal bars represent means and whiskers SEM. FC, fold change. Two-sided Mann-Whitney test. b) Analysis of clonogenic growth upon shRNA-mediated RRM2 silencing in EwS cell lines (A-673, ES7, TC-71) harboring Dox-inducible shRRM2 constructs or non-targeting shRNA (shControl). Horizontal bars represent means and whiskers SEM. Two-sided Mann-Whitney test at the experimental endpoint.

Article Snippet: Slides were incubated with a polyclonal anti-RRM2 primary antibody (rabbit, 1:500, atlas antibodies, HPA056994) for 60 min at room temperature followed by incubation with a monoclonal secondary horseradish peroxidase (HRP)-coupled horse-anti-rabbit antibody with AEC+ as chromogen, counterstained by hematoxylin Gill’s formula (H-3401, Vector Laboratories, Germany).

Techniques: shRNA, Construct, MANN-WHITNEY

Journal: bioRxiv

Article Title: Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

doi: 10.1101/2021.03.04.433896

Figure Lengend Snippet: a) Integrative Gene Ontology (GO) enrichment analysis of gene expression microarray data generated in A-673 and ES7 cells after RRM2 silencing or pharmacological RRM2 inhibition by triapine (corresponding IC50 of 0.44 µM or 0.65 µM, respectively). b) Correlation of gene expression between RRM2 and CHEK1 or WEE1 in 166 EwS. Each dot represents an individual expression value. Solid red lines indicate a trend line created by a simple linear regression. P -values were calculated by a two-tailed t-test. c) Drug interaction and combination efficiency analysis between triapine and CHEK1 inhibitor (CCT245737) or WEE1 inhibitor (MK-1775) in 4 EwS cell lines (A-673, ES7, EW-7, TC-71) assessed by combination index. CI value < 1 indicative of synergistic, CI = 1 additive, and CI > 1 antagonistic d) Drug interaction and combination efficiency estimation between triapine and CHEK1 inhibitor (CCT245737) or WEE1 inhibitor (MK-1775) in A-673 EwS cell line assessed by SynergyFinder 2.0. ZIP synergy score > 10, likely to be synergistic; between -10 and 10, likely to be additive; < –10, likely to be antagonistic.

Article Snippet: Slides were incubated with a polyclonal anti-RRM2 primary antibody (rabbit, 1:500, atlas antibodies, HPA056994) for 60 min at room temperature followed by incubation with a monoclonal secondary horseradish peroxidase (HRP)-coupled horse-anti-rabbit antibody with AEC+ as chromogen, counterstained by hematoxylin Gill’s formula (H-3401, Vector Laboratories, Germany).

Techniques: Gene Expression, Microarray, Generated, Inhibition, Expressing, Two Tailed Test

Journal: bioRxiv

Article Title: Translational evidence for RRM2 as a prognostic biomarker and therapeutic target in Ewing sarcoma

doi: 10.1101/2021.03.04.433896

Figure Lengend Snippet: a) Distribution analysis of RRM2 mRNA expression in 166 EwS patients. Each dot represents individual RRM2 expression. b) Correlation analysis of CNVs at the RRM2 locus with RRM2 mRNA expression levels in primary EwS tumors (n=32). The solid line indicates a trend line estimated by a simple linear regression model. b) Correlation analysis of promoter methylation on five CpG sites with RRM2 expression levels in primary EwS tumors (n=40). The solid lines indicate trend lines estimated by a simple linear regression model.

Article Snippet: Slides were incubated with a polyclonal anti-RRM2 primary antibody (rabbit, 1:500, atlas antibodies, HPA056994) for 60 min at room temperature followed by incubation with a monoclonal secondary horseradish peroxidase (HRP)-coupled horse-anti-rabbit antibody with AEC+ as chromogen, counterstained by hematoxylin Gill’s formula (H-3401, Vector Laboratories, Germany).

Techniques: Expressing, Methylation

Journal: Bioengineered

Article Title: A novel four-gene of iron metabolism-related and methylated for prognosis prediction of hepatocellular carcinoma

doi: 10.1080/21655979.2020.1866303

Figure Lengend Snippet: Immunohistochemical analysis of RRM2, FTCD, CYP2C9, and ATP6V1C1 in adjacent non-cancerous and cancerous tissues from HCC patients (original magnification, ×200)

Article Snippet: Then, sections were incubated with primary rabbit polyclonal anti-RRM2 antibody (1:50, 11661-1-AP, Proteintech, China), primary rabbit polyclonal anti-FTCD antibody (1:50, 21959-1-AP, Proteintech, China), primary rabbit polyclonal anti-CYP2C9 antibody (1:200, 16546-1-AP, Proteintech, China), and primary rabbit polyclonal anti-ATP6V1C1 antibody (1:50, 16054-1-AP, Proteintech, China) at 4 °C overnight, followed by an incubation with the corresponding secondary antibodies at 37 °C for 30 minutes.

Techniques: Immunohistochemical staining

Journal: Heliyon

Article Title: Tanshinone IIA attenuates fluoride-induced spinal cord injury by inhibiting ferroptosis and inflammation

doi: 10.1016/j.heliyon.2024.e40549

Figure Lengend Snippet: Primers used in qRT-PCR study.

Article Snippet: The membranes were then incubated overnight at 4 °C with primary antibodies against CXCL2 (26791-1-AP, Proteintech), PCK2 (67676-1-lg, abcam), RRM2 (DF7248, Affinity), SLC7A11 (BM5318, BOSTER), or β-actin (BA2305, BOSTER).

Techniques:

Journal: Heliyon

Article Title: Tanshinone IIA attenuates fluoride-induced spinal cord injury by inhibiting ferroptosis and inflammation

doi: 10.1016/j.heliyon.2024.e40549

Figure Lengend Snippet: Tanshinone IIA improved spinal cord injury by inhibiting ferroptosis (A) Photomicrographs of spinal cord sections from Tanshinone IIA control, fluoride-exposed rats, and Tanshinone IIA + high fluoride group visualized by transmission electron microscopy (5000X, white box). Fibrous myelin integrity (indicated by red arrows) is maintained in both Tanshinone IIA control and Tanshinone IIA-treated groups, while in the fluorosis group, it appears loosely arranged with an increased gap and disordered structure. (B) Scatter plot exhibited the expression of 15 ferroptosis-related genes in Tan IIA control, high fluoride group, and Tan IIA + high fluoride group. (C–D) Western blots showed that Tan IIA treatment restored the reduced protein expression of SLC7A11 and RRM2 observed in the NaF group. Additionally, Tan IIA treatment decreased the elevated protein levels of CXCL2 and PCK2 in the NaF group. Uncropped and unadjusted original images of the Western blots are provided in . Data are represented as the mean ± SEM (n = 6). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001.

Article Snippet: The membranes were then incubated overnight at 4 °C with primary antibodies against CXCL2 (26791-1-AP, Proteintech), PCK2 (67676-1-lg, abcam), RRM2 (DF7248, Affinity), SLC7A11 (BM5318, BOSTER), or β-actin (BA2305, BOSTER).

Techniques: Control, Transmission Assay, Electron Microscopy, Expressing, Western Blot

Journal: Annals of Hepato-Biliary-Pancreatic Surgery

Article Title: Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?

doi: 10.14701/ahbps.2020.24.2.127

Figure Lengend Snippet: Comparison of clinicopathologic factors based on the intensity of intratumoral hENT1 expression

Article Snippet: Immunohistochemical staining for hENT1 and dCK was performed using Anti-hENT1 rabbit polyclonal antibody (PAB2255, 1:120, Abnova, Taipei, Taiwan) and anti-dCK mouse monoclonal antibody (LS-C172855, 1:50, LSBio, Seattle, WA, USA)., RRM1 expression was evaluated with a polyclonal rabbit antibody against human RRM1 (ab81085, 1:100, Abcam, Cambridge, UK) and RRM2 with polyconal goat antibody against human RRM2 (SC-10846, 1:250, Santa Cruz Biotechnology, Dellas, TX, USA).

Techniques: Comparison, Adjuvant

Journal: Annals of Hepato-Biliary-Pancreatic Surgery

Article Title: Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?

doi: 10.14701/ahbps.2020.24.2.127

Figure Lengend Snippet: Univariate overall survival analysis for 160 patients

Article Snippet: Immunohistochemical staining for hENT1 and dCK was performed using Anti-hENT1 rabbit polyclonal antibody (PAB2255, 1:120, Abnova, Taipei, Taiwan) and anti-dCK mouse monoclonal antibody (LS-C172855, 1:50, LSBio, Seattle, WA, USA)., RRM1 expression was evaluated with a polyclonal rabbit antibody against human RRM1 (ab81085, 1:100, Abcam, Cambridge, UK) and RRM2 with polyconal goat antibody against human RRM2 (SC-10846, 1:250, Santa Cruz Biotechnology, Dellas, TX, USA).

Techniques: Adjuvant

Journal: Annals of Hepato-Biliary-Pancreatic Surgery

Article Title: Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?

doi: 10.14701/ahbps.2020.24.2.127

Figure Lengend Snippet: Kaplan-Meier survival curves. (A) Comparison of overall survival based on intensity of intratumoral hENT1 expression. There was no significant difference in overall survival. (B) High hENT1 expression group was compared with low hENT1 expression group, there was no statistical survival difference (HR, 1.16; 95% CI, 0.82-1.65, p =0.396). (C) When the group with gemcitabine therapy and high hENT1 expression was compared with all other patients, and no difference in overall survival was identified (HR, 0.99; 95% CI, 0.68-1.42; p =0.940).

Article Snippet: Immunohistochemical staining for hENT1 and dCK was performed using Anti-hENT1 rabbit polyclonal antibody (PAB2255, 1:120, Abnova, Taipei, Taiwan) and anti-dCK mouse monoclonal antibody (LS-C172855, 1:50, LSBio, Seattle, WA, USA)., RRM1 expression was evaluated with a polyclonal rabbit antibody against human RRM1 (ab81085, 1:100, Abcam, Cambridge, UK) and RRM2 with polyconal goat antibody against human RRM2 (SC-10846, 1:250, Santa Cruz Biotechnology, Dellas, TX, USA).

Techniques: Comparison, Expressing

Journal: Annals of Hepato-Biliary-Pancreatic Surgery

Article Title: Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?

doi: 10.14701/ahbps.2020.24.2.127

Figure Lengend Snippet: Kaplan-Meier survival curves. The association between intratumoral hENT1 expression and overall survival according to adjuvant chemotherapeutic agent. (A) Overall survival between the intensity of hENT1 expression within patients with gemcitabine therapy (HR, 0.92; 95% CI, 0.55-1.56; p =0.764). (B) The comparison between gemcitabine with high hENT1 expression group and other chemotherapy with low hENT1 did not show significant survival difference (HR, 0.81; 95% CI, 0.49-1.32; p =0.394).

Article Snippet: Immunohistochemical staining for hENT1 and dCK was performed using Anti-hENT1 rabbit polyclonal antibody (PAB2255, 1:120, Abnova, Taipei, Taiwan) and anti-dCK mouse monoclonal antibody (LS-C172855, 1:50, LSBio, Seattle, WA, USA)., RRM1 expression was evaluated with a polyclonal rabbit antibody against human RRM1 (ab81085, 1:100, Abcam, Cambridge, UK) and RRM2 with polyconal goat antibody against human RRM2 (SC-10846, 1:250, Santa Cruz Biotechnology, Dellas, TX, USA).

Techniques: Expressing, Adjuvant, Comparison

Journal: Cancer

Article Title: Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

doi: 10.1002/cncr.27739

Figure Lengend Snippet: Figure 1. Biomarker expression by was evaluated by immunohistochemistry. These photomicrographs reveal (a) low excision cross-complementing gene-1 (ERCC1) expression, (b) high ERCC1 expression, (c) low ribonucleotide reductase subunit M1 (RRM1) expression, (d) high RRM1 expression, (e) low ribonucleotide reductase subunit M2 (RRM2) expression, (f) high RRM2 expression, (g) low human equilibrative nucleoside transporter 1 (hENT1) expression, and (h) high hENT1 expression (original magnification, 400 in a-h).

Article Snippet: Tissue was reacted with anti-ERCC1 monoclonal antibody (clone 8F1; Neomarkers, Fremont, Calif), anti-RRM1 polyclonal antibody (clone AD203; ProteinTech, Chicago, Ill), anti-RRM2 monoclonal antibody (clone 1E1; SigmaAldrich, St. Louis, Mo), and anti-hENT1 polyclonal antibody (polyclonal SLC29A1a; Sigma-Aldrich) to determine levels of tumor expression of ERCC1, RRM1, RRM2, and hENT1, respectively.

Techniques: Biomarker Discovery, Expressing, Immunohistochemistry

Journal: Cancer

Article Title: Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

doi: 10.1002/cncr.27739

Figure Lengend Snippet: Figure 2. Overall survival (excluding 30-day mortality) is illustrated according to biomarker expression for (a) excision cross- complementing gene-1 (ERCC1), (b) ribonucleotide reductase subunit M1 (RRM1), (c) RRM2, and (d) human equilibrative nucleo- side transporter 1 (hENT1).

Article Snippet: Tissue was reacted with anti-ERCC1 monoclonal antibody (clone 8F1; Neomarkers, Fremont, Calif), anti-RRM1 polyclonal antibody (clone AD203; ProteinTech, Chicago, Ill), anti-RRM2 monoclonal antibody (clone 1E1; SigmaAldrich, St. Louis, Mo), and anti-hENT1 polyclonal antibody (polyclonal SLC29A1a; Sigma-Aldrich) to determine levels of tumor expression of ERCC1, RRM1, RRM2, and hENT1, respectively.

Techniques: Biomarker Discovery, Expressing

Journal: BMC cancer

Article Title: KAT7-acetylated YBX1 promotes hepatocellular carcinoma proliferation by reprogramming nucleotide metabolism.

doi: 10.1186/s12885-025-13708-w

Figure Lengend Snippet: Fig. 7 Construction of a cox survival prediction model by KAT7, YBX1, RRM2 and TK1 from TCGA-LIHC. A-C Prognosis comparison of HCC patients with KAT7/YBX1 (A), YBX1/RRM2 (B), or YBX1/TK1 (C) differential expression using Kaplan–Meier survival analysis. D The progression-OS status of the TCGA-LIHC set. E Time-dependent ROC analysis of 1-, 3-, and 5-years OS for HCC patients. F The calibration curve of 1-, 3-, and 5-years of the OS predicted by the model with a high accuracy. G Plots of model risk score and survival status distribution. H A novel COX nomogram containing risk scores for predicting OS in HCC patients. I The expression of KAT7, YBX1, RRM2, TK1 and lysine acetylation in xenograft tumors from different groups were analyzed by immunohistochemistry

Article Snippet: IHC staining was performed on 15 xenograft tumors at Chengdu Lilai Biological Technology Co., LTD (Chengdu, China) using primary antibody against KAT7 (1:50, CST), YBX1(1:100, Proteintech), RRM2(1:100, Proteintech) and TK1 (1:100, Proteintech).

Techniques: Comparison, Quantitative Proteomics, Expressing, Immunohistochemistry

Journal: BMC cancer

Article Title: KAT7-acetylated YBX1 promotes hepatocellular carcinoma proliferation by reprogramming nucleotide metabolism.

doi: 10.1186/s12885-025-13708-w

Figure Lengend Snippet: Fig. 8 Schematic model of the mechanism of KAT7 in HCC. KAT7 binds to YBX1, modulating its post-translational expression, and enhances the transcriptional activity of the central metabolic enzymes RRM2 and TK1

Article Snippet: IHC staining was performed on 15 xenograft tumors at Chengdu Lilai Biological Technology Co., LTD (Chengdu, China) using primary antibody against KAT7 (1:50, CST), YBX1(1:100, Proteintech), RRM2(1:100, Proteintech) and TK1 (1:100, Proteintech).

Techniques: Expressing, Activity Assay

Journal: Cancer

Article Title: Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

doi: 10.1002/cncr.27739

Figure Lengend Snippet: Figure 1. Biomarker expression by was evaluated by immunohistochemistry. These photomicrographs reveal (a) low excision cross-complementing gene-1 (ERCC1) expression, (b) high ERCC1 expression, (c) low ribonucleotide reductase subunit M1 (RRM1) expression, (d) high RRM1 expression, (e) low ribonucleotide reductase subunit M2 (RRM2) expression, (f) high RRM2 expression, (g) low human equilibrative nucleoside transporter 1 (hENT1) expression, and (h) high hENT1 expression (original magnification, 400 in a-h).

Article Snippet: Tissue was reacted with anti-ERCC1 monoclonal antibody (clone 8F1; Neomarkers, Fremont, Calif), anti-RRM1 polyclonal antibody (clone AD203; ProteinTech, Chicago, Ill), anti-RRM2 monoclonal antibody (clone 1E1; SigmaAldrich, St. Louis, Mo), and anti-hENT1 polyclonal antibody (polyclonal SLC29A1a; Sigma-Aldrich) to determine levels of tumor expression of ERCC1, RRM1, RRM2, and hENT1, respectively.

Techniques: Biomarker Discovery, Expressing, Immunohistochemistry

Journal: Cancer

Article Title: Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

doi: 10.1002/cncr.27739

Figure Lengend Snippet: Figure 2. Overall survival (excluding 30-day mortality) is illustrated according to biomarker expression for (a) excision cross- complementing gene-1 (ERCC1), (b) ribonucleotide reductase subunit M1 (RRM1), (c) RRM2, and (d) human equilibrative nucleo- side transporter 1 (hENT1).

Article Snippet: Tissue was reacted with anti-ERCC1 monoclonal antibody (clone 8F1; Neomarkers, Fremont, Calif), anti-RRM1 polyclonal antibody (clone AD203; ProteinTech, Chicago, Ill), anti-RRM2 monoclonal antibody (clone 1E1; SigmaAldrich, St. Louis, Mo), and anti-hENT1 polyclonal antibody (polyclonal SLC29A1a; Sigma-Aldrich) to determine levels of tumor expression of ERCC1, RRM1, RRM2, and hENT1, respectively.

Techniques: Biomarker Discovery, Expressing